AK 114

Drug Profile

AK 114

Alternative Names: AK114

Latest Information Update: 21 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Akeso Biopharma
  • Class Antibodies; Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Autoimmune disorders; Eye-Disorders

Most Recent Events

  • 21 Mar 2018 AK 114 is available for licensing as of 21 Mar 2018. http://www.akesobio.com
  • 21 Mar 2018 Preclinical trials in Autoimmune disorders in China (unspecified route) (Akeso Biopharma pipeline, March 2018)
  • 21 Mar 2018 Preclinical trials in Eye disorders in China (unspecified route) (Akeso Biopharma pipeline, March 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top